

OriGene Technologies Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES

Phone: +1-888-267-4436 Fax: +1-301-340-8606 techsupport@origene.com AP55541CP-N

OriGene EU

Acris Antibodies GmbH

Schillerstr. 5 32052 Herford GERMANY

Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info@acris-antibodies.com

EIG121 (C-term) Control Peptide

Catalog No.: AP55541CP-N

Quantity: 50 μg Concentration: 0.2 mg/ml

NCBI: NP 065826

GenelD: <u>1957</u>

Format: State: Liquid peptide

Buffer System: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing

0.1% BSA and 0.02% Sodium azide

Applications: The peptide is used for blocking the activity of EIG121 antibody Cat.-No. AP55541PU-N. It

usually blocks the antibody activity completely in Western blot by incubating the peptide

with equal volume of antibody for 30 min at 37°C.

Other applications not tested. Optimal dilutions are dependent on conditions and should

be determined by the user.

Specificity: Control peptide for AP55541PU-N. Peptide containing 18 amino acids near the carboxy

terminus of human EIG121.

Species: Human

Other species not tested.

Storage: Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.

Avoid repeated freezing and thawing. Shelf life: one year from despatch.

General Readings: Deng L, Broaddus RR, McCampbell A, et al. Identification of a novel estrogen-regulated

gene, EIG121, induced by hormone replacement therapy and differentially expressed in type

I and type II endometrial cancer. Clin. Cancer Res. 2005; 11:8258-64.

Pictures: Western blot analysis in MCF7 cell lysate

with EIG121 antibody Cat.-No AP55541PU-N at $1 \mu g/ml$ in (A) the absence and (B) the presence of blocking peptide.

